BioWorld

June 17, 2002

FDA Asks Biogen To Clarify Info On Amevive, But No Trial Needed

The FDA's positive feedback on Biogen Inc.'s Amevive application likely will be the first in a series of key events expected to drive the biotechnology industry this year, an analyst said.(BioWorld Today) Read More

SciClone Gets $10.6M 'Insurance' Financing To Advance Zadaxin

Air Strikes, Not Ground Attacks, To Destroy Immune Cytokines Of Lethal Graft-Versus-Host Disease

Abbott Reports Positive Data From Anti-TNF RA Antibody

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 16, 2026

GLP-1s need technologies for long-term use

BioWorld

For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...

UTRN gene involved in arthrogryposis, study finds

BioWorld Science

Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...

mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles

mRNA flu vaccine can activate broad germinal center response

BioWorld

On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers...